<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### [New spike structures (Oct 08)](/page/spike-structures/#figure.11.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.spike.receptor.binding.domain.rbd.)
Figure 11. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) spike receptor binding domain (RBD).

### [New spike structures (Oct 08)](/page/spike-structures/#figure.12.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.trimeric.spike.)
Figure 12. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) trimeric spike.

### Webinar (Oct 07)
Monoclonal Antibodies for the Prevention and Treatment of COVID 19. [video](https://www.youtube.com/watch?v=YUj9jBlTCrY)

### [Press Release (Oct 07)](/page/press-release)
- [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly202010071.pdf)
- [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly202010072.pdf)

### Data Base Entries(Oct 05)
Ansarin K, Tolouian R, et int., and Chapman KR. [‚ÄúEffect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.‚Äù](/search/?article=Ansarin20) _BioImpacts_, 2020. [doi.org/10.34172/bi.2020.27](https://doi.org/10.34172/bi.2020.27). \[[PubMed32983936](https://www.ncbi.nlm.nih.gov/pubmed/32983936/)\] \[[PMC7502909]\](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502909/)
### Data Base Entries(Oct 05)
Wahl A, Gralinski L, et int., and Garcia JV. [‚ÄúAcute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.‚Äù](/search/?article=Wahl20) _Research square_, [2020. doi.org/10.21203/rs.3.rs-80404/v1](https://doi.org/10.21203/rs.3.rs-80404/v1). \[[PubMed32995766](https://www.ncbi.nlm.nih.gov/pubmed/32995766/)\] \[[PMC7523135](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523135/)\]
### Data Base Entries(Oct 03)
Jones BE, Brown-Augsburger PL, et int., and Falconer E. [‚ÄúLY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.‚Äù](/search/?article=Jones20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.30.318972](https://doi.org/10.1101/2020.09.30.318972).
### Data Base Entries(Oct 03)
Sagar S, Rathinavel AK, et int., and Radhakrishnan P. [‚ÄúBromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells.‚Äù](/search/?article=Sagar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.16.297366](https://doi.org/10.1101/2020.09.16.297366). \[[PubMed32995771](https://www.ncbi.nlm.nih.gov/pubmed/32995771/)\] \[[PMC7523097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523097/)\]
### Data Base Entries(Oct 03)
Watson A, Ferreira L, et int., and Stroud R. [‚ÄúPeptide Antidotes to SARS-CoV-2 (COVID-19).‚Äù](/search/?article=Watson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.06.238915](https://doi.org/10.1101/2020.08.06.238915).

### [Press Release (Oct 02)](/page/press-release)

[Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Synairgen20200930.pdf)

### [Press Release (Oct 02)](/page/press-release)

[Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly20200930.pdf)

### [Press Release (Oct 02)](/page/press-release)

[Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Regeneron20200930.pdf)

### [Clinical Trials (Oct 01)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-01)

### Data Base Entries (Oct 01)
Proud PC, Tsitoura D, et int., and Carroll MW. [‚ÄúProphylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.‚Äù](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
### Data Base Entries (Oct 01)
Son J, Huang S, et int., and Ding S. [‚ÄúNitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.‚Äù](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
### Data Base Entries (Oct 01)
Fagre AC, Manhard J, et int., and Schountz T. [‚ÄúA potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.‚Äù](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
### Data Base Entries (Oct 01)
Lin C, Li Y, et int., and Chen J. [‚ÄúCeftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.‚Äù](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
### Data Base Entries (Oct 01)
Xiao T, Lu J, et int., and Chen B. [‚ÄúA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.‚Äù](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
### Data Base Entries (Oct 01)
Zhang L, Cao L, et int., and Zhu F. [‚ÄúA proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.‚Äù](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### Data Base Entries (Sep 29)
Brunaugh AD, Seo H, et int., and Smyth HD. [‚ÄúBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.‚Äù](/search/?article=Brunaugh20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
### Data Base Entries (Sep 29)
Curreli F, Victor SMB, et int., and Debnath AK. [‚ÄúStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Curreli20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
### Data Base Entries (Sep 25)
Ellen ter B, Dinesh Kumar N, et int., and Smit J. [‚ÄúResveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.‚Äù](/search/?article=Ellen%20ter20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).
### Data Base Entries (Sep 24)
Pereda R, Gonz√°lez D, et int., and Dom√≠nguez RE. [‚ÄúTherapeutic Effectiveness of Interferon-Œ±2b Against COVID-19: The Cuban Experience.‚Äù](/search/?article=Pereda20)¬†_Journal of Interferon & Cytokine Research_,¬†2020.¬†[doi.org/10.1089/jir.2020.0124](https://doi.org/10.1089/jir.2020.0124).¬†\[[PubMed32960147](https://www.ncbi.nlm.nih.gov/pubmed/32960147/)\]

### [Clinical Trials (Sep 24)](/page/updates/#clinical.trials)
[10 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-09-04)

### [New spike structure (Sep 24)](/page/updates/#features)
We added a figure [Naturally occurring spike RBD variants and mAb escape mutations](/page/spike-structures/#fig10).

### [New table added (Sep 24)](/page/updates/#features)
We added a [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/) and data for six monoclonal antibodies.

### Data Base Entries (Sep 23)
Cao L, Goreshnik I, et int., and Baker D. [‚ÄúDe novo design of picomolar SARS-CoV-2 miniprotein inhibitors.‚Äù](/search/?article=Cao20e)¬†_Science_,¬†2020.¬†[doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909).¬†\[[PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]

### [Interface update (Sep 22)](/page/updates/#features)
We now support downloading CSV/Excel files for tables.

### [Editorial (Sep 21)](/page/updates/#papers)

Shafer R. ‚ÄúA SARS-CoV-2 antiviral therapy score card‚Äù _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

### [Preprints => Peer-Reviewed Publications (Sep 16)](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added.

### Data Base Entries (Sep 15)
Li T, Han X, et int., and Jin A. [‚ÄúA key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.‚Äù](/search/?article=Li20e)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.11.292631](https://doi.org/10.1101/2020.09.11.292631).
### Data Base Entries (Sep 14)
Cohen-Dvashi H, Weinstein J, et int., and Diskin R. [‚ÄúCoronacept ‚Äì a potent immunoadhesin against SARS-CoV-2.‚Äù](/search/?article=Cohen-Dvashi20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.12.247940](https://doi.org/10.1101/2020.08.12.247940).
### Data Base Entries (Sep 14)
Glasgow A, Glasgow J, et int., and Wells JA. [‚ÄúEngineered ACE2 receptor traps potently neutralize SARS-CoV-2.‚Äù](/search/?article=Glasgow20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.31.231746](https://doi.org/10.1101/2020.07.31.231746).¬†\[[PubMed32766586](https://www.ncbi.nlm.nih.gov/pubmed/32766586/)\]¬†\[[PMC7402043](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402043/)\]
### Data Base Entries (Sep 14)
Hassan AO, Case JB, et int., and Diamond MS. [‚ÄúA SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.‚Äù](/search/?article=Hassan20)¬†_Cell_,¬†2020.¬†[doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011).¬†\[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\]¬†\[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Data Base Entries (Sep 14)
Olaleye OA, Kaur M, et int., and Adebusuyi T. [‚ÄúDiscovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro.‚Äù](/search/?article=Olaleye20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.14.250480](https://doi.org/10.1101/2020.08.14.250480).¬†\[[PubMed32817951](https://www.ncbi.nlm.nih.gov/pubmed/32817951/)\]¬†\[[PMC7430586](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430586/)\]
### Data Base Entries (Sep 14)
de Vries M, Mohamed AS, et int., and Dittmann M. [‚ÄúComparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.‚Äù](/search/?article=Vries20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.28.272880](https://doi.org/10.1101/2020.08.28.272880).¬†\[[PubMed32869028](https://www.ncbi.nlm.nih.gov/pubmed/32869028/)\]¬†\[[PMC7457613](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/)\]
### Data Base Entries (Sep 14)
Zhang Q, Chen CZ, et int., and Ye Y. [‚ÄúHeparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro.‚Äù](/search/?article=Zhang20e)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.14.202549](https://doi.org/10.1101/2020.07.14.202549).¬†\[[PubMed32699847](https://www.ncbi.nlm.nih.gov/pubmed/32699847/)\]¬†\[[PMC7373127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373127/)\]
### Data Base Entries (Sep 08)
Agarwal A, Mukherjee A, et int., and Abraham P. [‚ÄúConvalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial).‚Äù](/search/?article=Agarwal20)¬†_medRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.03.20187252](https://doi.org/10.1101/2020.09.03.20187252).
### Data Base Entries (Sep 08)
Bansal S, Jonsson CB, et int., and C√©sar Vega J. [‚ÄúIota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture.‚Äù](/search/?article=Bansal20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.19.225854](https://doi.org/10.1101/2020.08.19.225854).
### Data Base Entries (Sep 08)
Chan KK, Dorosky D, et int., and Procko E. [‚ÄúEngineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.‚Äù](/search/?article=Chan20)¬†_Science_,¬†2020.¬†[doi.org/10.1126/science.abc0870](https://doi.org/10.1126/science.abc0870).¬†\[[PubMed32753553](https://www.ncbi.nlm.nih.gov/pubmed/32753553/)\]
### Data Base Entries (Sep 08)
Zhu H, Chen CZ, et int., and Huang R. [‚ÄúMining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.‚Äù](/search/?article=Zhu20e)¬†__,¬†2020.
